Polypharmacy is associated with adverse events and multimorbidity, but data are limited on its association with specific comorbidities in primary care settings. We measured the prevalence of polypharmacy and inappropriate prescribing, and assessed the association of polypharmacy with specific comorbidities.
Introduction
With the increasing life expectancy worldwide, a higher proportion of individuals not only get older [1] , but are also more likely to develop multiple chronic conditions [2] [3] [4] . Most chronic conditions (comorbidities) are covered by disease-specific clinical guidelines using a single disease framework; this leads physicians to recommend drug treatments for each condition separately, which may lead to polypharmacy and drug-drug and drug-disease interactions [5] . In addition, to lower the risk of developing future medical conditions, research in preventive medicine has uncovered multiple risk factors, particularly in cardiovascular medicine, that also need treatment, thus increasing the number of people on regular multiple drug therapy [6, 7] . Furthermore, patients are often seen by multiple specialist physicians who prescribe drugs that primary care physicians are often reluctant to stop [8] .Polypharmacy, commonly defined as the concurrent use of 5 or more long-term prescribed drugs, is frequent and increasing in prevalence [4, 7, [9] [10] [11] [12] [13] [14] . The use of multiple drugs is associated with potential unforeseen medical consequences, such as adverse drug events, drug monitoring errors, unplanned hospitalizations, and sometimes fatal outcomes [5, [15] [16] [17] [18] [19] . The risk of drug-drug interaction increases with the number of prescribed drugs: 13% of patients on 2 concurrent drugs experience drug-drug interaction, but this risk rises to 38% for those on 5 drugs and 82% for those on ≥7 drugs [20] .
Moreover, polypharmacy is associated with poor adherence, lower physical and social function, higher healthcare costs, and decreased quality of life [13, 16, 19] . Additionally, inappropriate prescribing, including both over-(potentially inappropriate prescribing [PIP] ) and underprescription (potential prescribing omission [PPO] ) is also associated with poor outcome, such as increase in adverse drug events [21] . While polypharmacy is relatively well defined, the definition of multimorbidity is not consistent in the literature; a common definition is 2 or more comorbidities [3] .
Prior epidemiological studies conducted in several other countries found a prevalence of polypharmacy ranging from 12 to 48% in patients aged 50 years or older [9, 10, 13, 14, 22] , but data remain limited on associations between polypharmacy and specific comorbidities, like cardiovascular ones [13] . In Switzerland, a country with universal healthcare coverage, only one study assessed the prevalence of polypharmacy and PIP, based on claims data from a health insurer company without clinical information on diagnosis. Except for this study, data on PIP and PPO in Switzerland are limited, with studies including only hospitalized geriatric [23] or mentally-ill patients [24] .
We therefore aimed to measure the prevalence of polypharmacy, PIP and PPO in university primary care settings, and to assess the association of polypharmacy with specific comorbidities, in order to uncover subgroups of patients at higher risk of polypharmacy.
Material and methods

Study population
We abstracted medical records from 1002 randomly selected patients followed for at least one year by primary care physicians in all but one Swiss university primary care clinics (Basel, Geneva, Lausanne and Zurich) in a retrospective cohort study, as previously described [25] . For this analysis, we used cross-sectional data of the baseline visit. These community-dwelling patients were randomly identified from electronic administrative data of all patients aged 50 to 80 years and followed in [2005] [2006] . The selection was limited to this age group to ensure a high prevalence of cardiovascular risk factors and other conditions that are targeted by preventive care and medical treatment. About 90% of the patients were cared for by residents in general internal medicine supervised by senior physicians. The remaining 10% were cared by senior physicians directly.
We initially identified 1889 patients, among which 54 charts could not be found, probably because the patients had left the clinic for another ambulatory practice. We excluded 125 patients because they had no outpatient visit to a primary care physician, and 117 that were followed only in a specialized care setting during this period. In order to ensure adequate time and information to assess preventive care, we excluded another 591 patients who had less than one year follow-up in the university primary care setting during the review period.
Definitions of polypharmacy and multimorbidity
We recorded only long-term prescribed drugs at the first visit of the review period; prescriptions for acute conditions, like antibiotics or temporary painkillers, were not taken into account. Similarly to previous studies, we defined polypharmacy as 5 or more long-term prescribed drugs [9, 12, 14, 26, 27] .
We found no consistent definition to select comorbidities in prior scientific literature [28] . The length of comorbidity lists ranged from 7 to 46 different comorbidities [13, [29] [30] [31] . We therefore established a new list including 17 comorbidities (Table A) , as previously described [32] , based on a large study by Higashi et al. [33] and on the Charlson index [34] . We added psychiatric conditions (e.g. schizophrenia, depression) as an important comorbidity [35] , based on a consensus of the above mentioned references and between the authors. Additionally, we defined specific subgroups of comorbidities: 1) cardiovascular diseases: history of transient ischemic attack, cerebral vascular accident, coronary artery disease, angina, myocardial infarction, congestive heart failure and/or peripheral vascular disease; 2) chronic pulmonary diseases: chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, sarcoidosis, pulmonary hypertension, bronchiectases, interstitial pulmonary disease and/or global respiratory insufficiency; 3) psychiatric diseases: depression, bipolar disorder, psychosis, schizophrenia and/or pervasive development disorder. For sensitivity analyses, we used subcategories of cardiovascular disease (cerebral vascular disease, ischemic heart disease, heart failure). As did others [3, 29] , we defined multimorbidity as the presence of 2 or more of these comorbidities [32] , but also assessed the number of comorbidities as a count variable.
Potentially inappropriate prescribing and potentially prescribing omission
PIP and PPO were measured using the Screening Tool of Older People's Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) criteria [36] . As the criteria were developed for individuals aged ≥65 years, we applied them to this subgroup of our patients, and then performed a sensitivity analysis including our whole population. As we had detailed clinical information on cardiovascular disease and cardiovascular risk factors, we only applied the STOPP/START criteria for cardiovascular and anti-diabetic drugs when all detailed clinical information was available. Therefore, we applied 7 STOPP (i.e. A3, B3, B6, C1, C7, J1, J2) and 4 START (i.e. A3, A4, A5, A7) criteria related to these drugs. One author (CEA) checked the whole database for PIP and PPO. A 5% random sample was checked for accuracy by a second author (SS). The agreement between the 2 reviewers was 98.0% and the 2.0% disagreement was solved by discussion. PIP and PPO were defined as the percentage of patients with at least 1 unfulfilled STOPP and START criteria, respectively.
Statistical Analyses
We counted the number of drugs as a whole (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, ≥10), as well as stratified by 5-year age groups and by the number of comorbidities (0, 1, 2, 3-4, 5-6, ≥7). We compared baseline characteristics between patients with and those without polypharmacy using t-test and chi-square test where appropriate.
We used a logistic mixed-effects regression model, crude and adjusted for age, gender, civil status and occupation, to assess the association of polypharmacy with the number of comorbidities, presence of multimorbidity, smoking status, body mass index (BMI), specific comorbidities, subgroups of comorbidities (psychiatric diseases, dementia, cardiovascular diseases, diabetes mellitus, hypertension, chronic pulmonary diseases, cancer and chronic kidney disease), PIP and PPO. Results were presented as odds ratio (OR) with 95% confidence intervals (CI).
We used a multilevel mixed-effects Poisson regression model, crude and adjusted for the same parameters, to assess the association between the number of drugs as a count variable with the same variables as in the previous model. Results were presented as incidence rate ratios (IRR) with 95%CI.
We used the mixed-effects models to account for the clustering of patients within the different treating physicians and treatment centers. We performed all statistical analyses using STATA release 13.1 (StataCorp, College Station, TX). All p-values were 2-sided at a 0.05 level of significance. The association between polypharmacy, number of drugs and age Figure 1a shows the percentage of patients on a particular number of drugs according to age group.
Results
Patients characteristics
Patients with polypharmacy were significantly older than patients on less than 5 drugs (p<0.0001, Table   1 ). The prevalence of polypharmacy was 20.8% (41/197) in the youngest age group (50-54 years), 45.6% (194/426) in the patients aged 65 years or older, and 54.8% (63/115) in the oldest age group (75-80 years). The oldest age group had the highest odds for polypharmacy compared to the youngest age group in adjusted analysis (OR 4.73, 95% CI 2.46-9.10, Table 2 ). In the highest age group, the number of drugs was 29% higher than in the lowest age group (IRR 1.29, 95% CI 1.07-1.56, Table 3 ).
The association of polypharmacy, number of drugs and comorbidities
The number of drugs increased significantly with the number of comorbidities. In patients with 4 or more comorbidities, all but 2 patients (9.2%) had at least 1 drug. Among the patients with at least 7 comorbidities, 84.9% had polypharmacy (Figure 1b) . This association remained significant in multivariate analyses; even after adjustment for demographics, patients with multimorbidity had a far higher odds for polypharmacy (OR 6.14, 95% CI 4.16-9.08, Table 2 ) and an increased number of drugs (IRR 1.91, 95% CI 1.72-2.13, Table 3 ) compared to patients without multimorbidity. For each additional comorbidity, patients were more likely to have more prescribed drugs (IRR 1.18, 95% CI 1.15-1.20).
Hypertension had the strongest association with polypharmacy (OR 8.49, 95% CI 5.25-13.73) and the number of drugs (IRR 2.10, 95% CI 1.87-2.36). Cardiovascular diseases, diabetes mellitus, BMI and chronic kidney disease were also independently associated with polypharmacy and the number of drugs (Tables 2 and 3 ). Chronic pulmonary diseases were weakly associated with the number of drugs, but not with polypharmacy (Tables 2 and 3 
Polypharmacy, number of drugs and other clinical variables
Being employed was associated with a lower number of drugs when compared with other social status (on social aid, unemployed, at home, in education, or retired), and with a lower prevalence of polypharmacy when compared with being on social aid or unemployed (Tables 2 and 3 ). These associations were less strong after adjusting for the number of comorbidities (data not shown). Civil status was associated neither with polypharmacy nor with the number of drugs. Finally, male gender was only slightly associated with the number of drugs, but not with polypharmacy (Tables 2 and 3) . Table 4 describes the prevalence of each STOPP/START criterion in patients aged ≥65 years and in the whole patient population. In patients aged ≥65 years, the prevalence of PIP was 5.9%; it was higher among patients with polypharmacy (9.3% versus 3.0% in those without, p=0.006, Table 1 ) and strongly associated with polypharmacy (OR 3.72, 95% CI 1.47-9.44, Table 2 ) and with the number of drugs (IRR 1.35, 95% CI 1.12-1.64, Table 3 ). Almost one third (32.2%) of the patients had PPO. PPO was associated neither with polypharmacy nor with the number of drugs (Tables 2 and 3) . Forty-eight patients had more than 1 PPO. Omitting antiplatelet (START criterion A3) and statin (START criterion A5) therapies with a documented history of coronary, cerebral, or peripheral vascular disease were the 2 most prevalent PPO, accounting for 70.7% of the PPOs. We found similar results in the whole study population (Tables 2, 3 
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and 4).
Discussion
In this random sample of primary care patients aged 50-80 years, we found that 37% had polypharmacy, and 4% received 10 drugs or more. The prevalence of PIP was significantly higher among patients with polypharmacy. Multimorbidity, age, and specific comorbidities, such as hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, were associated with polypharmacy, while other subgroups of comorbidities (psychiatric diseases, dementia, chronic pulmonary diseases, cancer) were not. The association was particularly strong for hypertension.
The prevalence of polypharmacy in our study was consistent with prior epidemiological studies conducted in other high income countries in patients aged 50 years or older: a large Swedish study found a prevalence of polypharmacy of 12-38% in the age group 50-79 years [9] , while it ranged from 13 to 48% for the same age range in a study using electronic primary care records in Scotland [13] , and was 29% in patients aged 57-85 years in the USA [14] . When focusing on patients aged 65 years or older, the prevalence of polypharmacy in our study (46%) was also consistent with previous data from an Italian community-dwelling population (46%) [22] .
The strong association of multimorbidity and the number of comorbidities with polypharmacy and the number of drugs is consistent with previous data [13, 14, 31] . This may reflect the disease-specific guidelines that are still usually applied for initiating drug treatments. However, patients with multimorbidity are often excluded from, and less than 5% explicitly included in randomized controlled trials on which these recommendations are based [37]; thus, applying them to these patients may be inappropriate [19, 38] . The strong association between PIP and polypharmacy is consistent with previous data using the same criteria for PIP [23] . This observation highlights the importance to reconsider each prescription in patients receiving polypharmacy. For this purpose, the STOPP/START criteria may help [36, 39] ; however, as the application of the whole criteria set is time-consuming and therefore difficult to implement in everyday clinical practice, software solutions are under development.
Finally, physician's clinical judgment and shared decision making are central in the process of prescription.
The United Kingdom Prospective Diabetes Study (UKPDS) in patients with type 2 diabetes showed that 29% of the patients needed at least 3 different drugs to reach a blood pressure target of <150/85mmHg
[40], while the recommended goal in this population is far lower (<130/80mmHg) [41] . Additionally, because hypertension, diabetes mellitus and chronic kidney disease are strongly related to cardiovascular diseases, patients with these comorbidities often receive additional drugs recommended in both primary and secondary prevention (e.g. aspirin, statins) [19, [42] [43] [44] . The association of these cardiovascular risk factors and cardiovascular diseases with polypharmacy is consistent with previous data [13, 45] . Interestingly, we found a stronger association of polypharmacy with hypertension than with cardiovascular disease. The interpretation of this finding is limited by our broad classification of cardiovascular disease, which was associated with some heterogeneity (e.g. stronger association of polypharmacy with heart failure than with stroke). Surprisingly, we found no association between polypharmacy and psychiatric disorders. This probably reflects the reality of patients cared in ambulatory general internal medicine. Psychiatric conditions that are mostly managed with drugs (e.g. schizophrenia) [46] were indeed rather rare (6% of the patients having a psychiatric condition in our study had schizophrenia), while more prevalent conditions like personality disorder (25% of the patients having a psychiatric condition in our study) are often managed without any drug as first line therapy. On the other hand, patients followed in specialized psychiatric settings may have more severe conditions needing multiple medications, thus polypharmacy may be more prevalent among them. We also found no association with dementia, but our study included only 24 patients with this condition. Preventive drugs might have been discontinued in these patients with formally diagnosed dementia, as dementia is associated with shortened life expectancy and decreased quality of life [47] .
In our study, there was no significant association between cancer and polypharmacy, which is consistent with the study by Payne et al. (12) that found a similar mean number of drugs among this subgroup of patients (4 drugs). On the opposite, a review of previous studies in patients with advanced cancer showed a high prevalence of polypharmacy among them [48] . This discrepancy is probably due to different settings (in-hospital versus ambulatory) and study population (advanced versus not advanced cancer).
Patients who were unemployed, receiving social aid, at home, in education or retired, were prescribed a higher number of drugs than patients that were employed. Interestingly, this association was stronger for patients unemployed or receiving social aid than for patients being at home, in education or retired.
This finding may be partially explained by a higher number of comorbidities, as the association of occupation status and polypharmacy was weakened by adjusting for the number of comorbidities. This is consistent with data showing a higher prevalence of multimorbidity in the most deprived population, among which multimorbidity would occur on average 10 to 15 years earlier [3] . However, as this association didn't disappear after adjustment for the number of comorbidities, we can hypothesize additional explanations for this finding: deprived patients may have lower income and/or education, which has been associated with polypharmacy [10, 13, 49] ; they may also more likely consult with a prescription purpose, as suggested previously [49] .
Although the community-dwelling individuals in our study differed from older frail nursing home residents, those with multimorbidity are at higher risk of polypharmacy as they become older. Although the patterns of drugs are different in nursing home and in the community, e.g. with a higher number of pain-killers and psychotropic drugs [50-52], optimizing medication in the community-dwelling individuals is also central in order to optimize care and reduce polypharmacy.
There are some limitations to our study. First, our results are based on retrospective medical chart review, with potential underreporting; however, a previous study comparing process-based quality scores using standardized patients, clinical vignettes and abstraction of medical charts found that measurement of quality of care using abstraction of medical charts was about 5% lower than using clinical vignettes and 10% lower than using standardized patients [53] . Second, we restricted our analyses to patients aged 50 to 80 years and can therefore not draw conclusions for younger or older patients. Third, as we could apply a subset of the STOPP/START criteria only, we could not compare the prevalence of PIP and PPO with data of other previous studies. Fourth, we conducted only a crosssectional analysis without assessing the impact of polypharmacy and STOPP/START criteria on patient's related health outcomes Finally, our results may not be totally generalizable to primary care settings in general for several reasons: we could not assess other parameters of socioeconomic status, such as income and education, because of the lack of reliable information on these variables in the medical charts, and, in Switzerland, there are generally more forced migrants and patients with lower socioeconomic status in university primary care settings, which has been associated with an earlier occurrence of multimorbidity [3] . The prevalence of some comorbidities, like hypertension, may also be higher in these settings [32] . Furthermore, almost all patients were cared by residents at the end of their postgraduate training, who may be more adherent to medical guidelines [25] .
Learning points:
Ø In university primary care settings, 37.0% of patients have ≥5 chronic drugs (4.1% ≥10), and potentially inappropriate prescribing is more frequent among participants with polypharmacy (11.9% vs. 3.7%, p<0.0001).
Ø Several specific comorbidities, particularly hypertension, diabetes mellitus, chronic kidney disease and cardiovascular diseases, are strongly associated with polypharmacy.
Ø Future trials should include multimorbid patients, in order to develop prescription guidelines adapted to this population at particular high risk of polypharmacy and potentially inappropriate prescribing.
Conclusions and clinical implications
In this random sample of primary care patients, we found that polypharmacy was highly prevalent in university primary care settings and strongly associated with age, multimorbidity, the number of comorbidities, and specific comorbidities, particularly hypertension, diabetes mellitus, chronic kidney disease, and cardiovascular diseases. This is clinically relevant, given the association of polypharmacy with adverse consequences, particularly in patients with multimorbidity [5] . Given that the prevalence of polypharmacy and multimorbidity will very probably further increase in the coming years, and that PIP is associated with polypharmacy, further randomized trials including multimorbid patients are needed in order to develop guidelines adapted to this particular population to help avoiding PIP and adverse drug events. As polypharmacy, the risk for drug-drug interactions and their associated negative consequences are significantly increased among the oldest old patients because of frailty and their higher number of comorbidities [54] , future studies should also plan to include oldest old patients, i.e. those aged more than 80 years.Waiting for any new specific recommendation for multimorbid elderly, specific indications for each drug should be very carefully reviewed, particularly in those patients. In the meantime, we suggest that the process of prescription relies on the use of criteria developed to avoid PIP and PPO (e.g. the STOPP/START criteria [36, 39]), accounting for physician's clinical judgment, estimated patient's life expectancy and patient's preferences.
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